Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Policy
SEC Charges Biotech R&D Head With Lying
by Michael McCoy
June 7, 2010
| A version of this story appeared in
Volume 88, Issue 23
The Securities & Exchange Commission has charged Elizabeth A. Dragon, the former senior vice president of R&D at biotech firm Sequenom, with making false statements to investors about her company’s prenatal test for Down syndrome. According to SEC, Dragon claimed that the test’s highly accurate results were obtained on a “blinded” basis. In fact, the agency alleges, Dragon “provided her scientists with the known outcomes of the samples, which allowed them to manipulate the data in order to produce more accurate results.” Dragon and Sequenom’s CEO were fired last year (C&EN, Oct. 5, 2009, page 23).
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X